ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 162 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2018. The put-call ratio across all filers is 2.52 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $14,639,000 | -33.2% | 393,839 | -7.8% | 0.26% | -18.3% |
| Q2 2020 | $21,923,000 | +79.4% | 427,268 | +10.2% | 0.32% | +69.1% |
| Q1 2020 | $12,220,000 | -30.6% | 387,583 | +31.3% | 0.19% | +4.4% |
| Q4 2019 | $17,596,000 | +2852.3% | 295,081 | +1716.2% | 0.18% | +2950.0% |
| Q3 2019 | $596,000 | -21.9% | 16,247 | -0.9% | 0.01% | -25.0% |
| Q2 2019 | $763,000 | +14.4% | 16,396 | -1.3% | 0.01% | +14.3% |
| Q1 2019 | $667,000 | -46.6% | 16,613 | -38.8% | 0.01% | -53.3% |
| Q4 2018 | $1,248,000 | +2.7% | 27,126 | -0.9% | 0.02% | +25.0% |
| Q3 2018 | $1,215,000 | +30.6% | 27,381 | +15.4% | 0.01% | +20.0% |
| Q2 2018 | $930,000 | -32.0% | 23,737 | +25.5% | 0.01% | -33.3% |
| Q1 2018 | $1,368,000 | -0.4% | 18,919 | -9.4% | 0.02% | +7.1% |
| Q4 2017 | $1,374,000 | +22.2% | 20,871 | -6.9% | 0.01% | +16.7% |
| Q3 2017 | $1,124,000 | – | 22,425 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,818,835 | $59,618,000 | 21.09% |
| Bellevue Group AG | 4,519,164 | $95,580,000 | 0.93% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,713,176 | $36,234,000 | 0.84% |
| Rhenman & Partners Asset Management AB | 572,267 | $12,103,000 | 0.82% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 64,434 | $1,363,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $10,575,000 | 0.37% |
| EMC Capital Management | 27,566 | $583,000 | 0.33% |
| WASATCH ADVISORS LP | 3,766,935 | $79,671,000 | 0.32% |
| Avidity Partners Management LP | 400,000 | $8,460,000 | 0.23% |
| Cinctive Capital Management LP | 186,170 | $3,937,000 | 0.18% |